Page 9 - Sun Pharma

Street concerns ease as Sun Pharma's specialty segment delivers in Q2

Upsides in the stock will depend on sustaining specialty and India sales growth

Sun Pharma gains 10% in two days on healthy September quarter results

The company said that sales of specialty products have improved sequentially with Ilumya and Cequa reaching pre-Covid levels

Sun Pharma's Q2 net profit rises 70% on one-time tax credit

Revenues remain flat, sequential improvement in India and US revenues

Financials lift indices; Sensex ends 504 pts up ahead of US poll outcome

All that happened in the markets today

Sun Pharma closes share buyback offer period; stock jumps 5%

The drug major is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in the US market

Sun Pharma bullish on specialty biz, looks to expand to new geographies

Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company''s strategy of developing the specialty business as an additional growth engine has started delivering results

Sun Pharma arm recalls one lot of diabetes drug Riomet ER oral in US

Sun Pharma has said it is voluntarily recalling one lot of Riomet ER oral suspension in the US market, due to the presence of a probable human carcinogen above the acceptable daily intake limit.

Stock picks by Prabhudas Lilladher: Buy Take Solutions, Sun Pharma

Sun Pharma's stock is in a rising trend

Covid-19 prescription: Pharma players shift their focus over the counter

The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment

Sun Pharma surges 4%, hits 52-week high; stock rallies 76% from March-low

For the quarter ended June 2020, Sun Pharma reported a surprise loss due to one-time charges.

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Sun Pharma, L&T: Stocks that Nilesh Jain of Anand Rathi is bullish on

Sun Pharma's counter has provided a fresh breakout after retesting its rising channel on the daily chart

Lupin, Sun Pharma recalling products in the US market, says USFDA

Leading drug makers Lupin and Sun Pharma are recalling different products in the US, according to the US Food and Drug Administration (USFDA).

Lupin launches Covid-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use of its product

SPARC back in the black in Q1, reports profit of Rs 57 cr; stock jumps 14%

It's revenue from operations for the quarter under review came in at Rs 185.45 crore, clocking a growth of 970.73 per cent YoY from Rs17.32 crore reported in Q1FY20

Sun Pharma launches cheapest favipiravir brand in India, at Rs 35 a pill

Pricing pressure in this category is already visible as Glenmark revised its original price (Rs 103 per tablet) to Rs 79 per tablet within a month of the launch

Will continue to focus on growing business faster than market: Sun Pharma

The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty revenues, Shanghvi said

Weak US outlook, pricing pressures weigh on Sun Pharma's revenue growth

Margin gains in the June quarter unlikely to sustain

Sun Pharma posts surprise Rs 2,184 cr Q1 pre-tax loss on one-time expense

Firm's US revenue dips 33.5%; one-time loss of Rs 3,633 cr pertains to $213.3 mn pzayment by Taro, a Sun Pharma subsidiary, for settlement of anti-trust cases in the US

Sun Pharma Q1 net loss at Rs 1,655.6 cr, revenue down to Rs 7,585.3 cr

The company had posted a net profit of Rs 1,387.48 crore for the corresponding period of the previous fiscal, Sun Pharma said in a BSE filing